CervoMed (CRVO) Depreciation & Amortization (CF) (2010 - 2021)
CervoMed (CRVO) posted Depreciation & Amortization (CF) of $19100.0 for Q3 2021, down 19.6% sequentially from $23755.0 in Q2 2021, and down 21.05% YoY from $24192.0 in Q3 2020.
CervoMed (CRVO) Depreciation & Amortization (CF) (2010 - 2021) Analysis & Trends
CervoMed has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $19100.0 in Q3 2021.
- Quarterly Depreciation & Amortization (CF) fell 21.05% year-over-year to $19100.0 in Q3 2021, while the trailing twelve-month figure through Jun 2022 was $19100.0 (down 80.38% YoY) and the FY2021 annual result came in at $93416.0, down 9.45% from the prior year.
- Depreciation & Amortization (CF) declined to $19100.0 in Q3 2021 per CRVO's latest filing, from $23755.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $34390.0 in Q2 2019 and troughed at $5790.0 in Q2 2017.
- A 5-year average of $23512.5 and a median of $26709.0 in 2018 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2017 and 2019: Depreciation & Amortization (CF) jumped 384.61% in 2017, then sank 34.78% in 2019.
- Over 5 years, Depreciation & Amortization (CF) stood at $28214.0 in 2017, then advanced by 2.51% to $28921.0 in 2018, then slipped by 6.38% to $27075.0 in 2019, then slipped by 7.9% to $24935.0 in 2020, then slipped by 23.4% to $19100.0 in 2021.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $19100.0, $23755.0, and $24447.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 19,100.00 |
| Sep 30, 2021 | 19,100.00 |
| Jun 30, 2021 | 23,755.00 |
| Jun 30, 2021 | 23,755.00 |
| Mar 31, 2021 | 24,447.00 |
| Mar 31, 2021 | 24,447.00 |
| Dec 31, 2020 | 24,935.00 |
| Dec 31, 2020 | 24,935.00 |
| Sep 30, 2020 | 24,192.00 |
| Sep 30, 2020 | 24,192.00 |
| Jun 30, 2020 | 27,021.00 |
| Jun 30, 2020 | 27,021.00 |
| Mar 31, 2020 | 27,020.00 |
| Mar 31, 2020 | 27,020.00 |
| Dec 31, 2019 | 27,075.00 |
| Dec 31, 2019 | 27,075.00 |
| Sep 30, 2019 | 18,178.00 |
| Sep 30, 2019 | 18,178.00 |
| Jun 30, 2019 | 34,390.00 |
| Jun 30, 2019 | 34,390.00 |